Sarepta Therapeutics, Inc.

Cambridge, MA

UEI
YKM9HZ3EH6X1
CAGE
49WU1
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
Corporate family
SAM.gov registration date
Physical address
215 First St, Cambridge, MA 02142, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
IM formulation feasiblity study W911QY12C0117 ACC Aberdeen Proving Ground $3,786,506
Antibacterial and anti-shiga N3239812P0306 Bureau of Medicine and Surgery (Navy) $100,000
The transformational medical N3239811P0317 Bureau of Medicine and Surgery (Navy) $99,000
Advanced development of hemorrhagic W9113M10C0056 ACC Aberdeen Proving Ground $106,393,196
H1N1 countermeasure development HDTRA110C0079 Defense Threat Reduction Agency $12,324,641

Latest 5 listed here. See the rest on GovTribe.

Grant awards

Quick answers

Is Sarepta Therapeutics, Inc. registered in SAM.gov?

Yes. Sarepta Therapeutics, Inc.'s SAM.gov registration is active through May 4, 2027.

What is Sarepta Therapeutics, Inc.'s most recent federal award?

Sarepta Therapeutics, Inc.'s most recent federal contract award is IM formulation feasiblity study (W911QY12C0117), from ACC Aberdeen Proving Ground, on August 23, 2012.

On GovTribe

See Sarepta Therapeutics, Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors